AMRN Stock Overview
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Amarin Corporation plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$1.49 |
| 52 Week Low | US$0.65 |
| Beta | 2.01 |
| 1 Month Change | -0.68% |
| 3 Month Change | -34.84% |
| 1 Year Change | -32.28% |
| 3 Year Change | -83.59% |
| 5 Year Change | -95.26% |
| Change since IPO | -99.86% |
Recent News & Updates
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Apr 16Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Mar 12
Recent updates
Amarin Corporation: Small Signs Of Recovery May Not Be Enough
Apr 16Little Excitement Around Amarin Corporation plc's (NASDAQ:AMRN) Revenues As Shares Take 27% Pounding
Mar 12Amarin: Sarissa Is Giving Me Hope Again
Jan 15Improved Revenues Required Before Amarin Corporation plc (NASDAQ:AMRN) Stock's 26% Jump Looks Justified
Jan 03Calculating The Fair Value Of Amarin Corporation plc (NASDAQ:AMRN)
Nov 19Investors Don't See Light At End Of Amarin Corporation plc's (NASDAQ:AMRN) Tunnel
Sep 27We Think Amarin (NASDAQ:AMRN) Can Afford To Drive Business Growth
Jul 18Is Amarin (NASDAQ:AMRN) In A Good Position To Deliver On Growth Plans?
Nov 11Amarin gains as activist Sarissa starts process for special meeting to replace some board members
Oct 11Amarin down 21% on higher than normal daily volume
Aug 22For Amarin, Something Wishful This Way Comes
Aug 14Amarin Q2 2022 Earnings Preview
Aug 02HLS Therapeutics gets reimbursement for Vascepa in Ontario
Jul 25Amarin's Vazkepa medicine gets final guidance from UK body for reimbursement and use
Jul 13Amarin extends losses after Stat report on cardiovascular therapy
Jun 30Amarin: Alex Denner, Health Net, Statin Combo, And Signs Of Better Times
Apr 19Here's Why We're Not At All Concerned With Amarin's (NASDAQ:AMRN) Cash Burn Situation
Feb 23Shareholder Returns
| AMRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.3% | 0.4% | 1.0% |
| 1Y | -32.3% | 0.9% | 21.9% |
Return vs Industry: AMRN underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: AMRN underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| AMRN volatility | |
|---|---|
| AMRN Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMRN's share price has been volatile over the past 3 months.
Volatility Over Time: AMRN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 275 | Pat Holt | www.amarincorp.com |
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers.
Amarin Corporation plc Fundamentals Summary
| AMRN fundamental statistics | |
|---|---|
| Market cap | US$353.22m |
| Earnings (TTM) | -US$59.11m |
| Revenue (TTM) | US$306.91m |
1.2x
P/S Ratio-6.0x
P/E RatioIs AMRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMRN income statement (TTM) | |
|---|---|
| Revenue | US$306.91m |
| Cost of Revenue | US$102.14m |
| Gross Profit | US$204.77m |
| Other Expenses | US$263.88m |
| Earnings | -US$59.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 66.72% |
| Net Profit Margin | -19.26% |
| Debt/Equity Ratio | 0% |
How did AMRN perform over the long term?
See historical performance and comparison